RGD Reference Report - Up-regulation of pS2 expression during the development of adenocarcinomas but not squamous cell carcinomas of the uterine cervix, independently of expression of c-jun or oestrogen and progesterone receptors. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Up-regulation of pS2 expression during the development of adenocarcinomas but not squamous cell carcinomas of the uterine cervix, independently of expression of c-jun or oestrogen and progesterone receptors.

Authors: Saegusa, M  Hashimura, M  Hara, A  Okayasu, I 
Citation: Saegusa M, etal., J Pathol. 2000 Apr;190(5):554-63.
RGD ID: 2298570
Pubmed: PMID:10727981   (View Abstract at PubMed)
DOI: DOI:10.1002/(SICI)1096-9896(200004)190:5<554::AID-PATH557>3.0.CO;2-V   (Journal Full-text)

The pS2 gene product was firstly identified as an oestrogen-induced molecule in a breast cancer cell line, while recent studies demonstrate a close association with mucus-secreting epithelia. To assess pS2 expression in uterine cervical adenocarcinomas (C-ACas) and invasive squamous cell carcinomas (C-ISCCs), a series of 94 and 86 cases, respectively, as well as 77 samples of normal cervix, were immunohistochemically investigated and the results compared with data for expression of oestrogen and progesterone receptors (ER and PR) and c-jun. RT-PCR and western blot assays were also applied to 21 cervical carcinomas and 24 normal tissues. With cervical glandular lesions, significant up-regulation of pS2 expression at both the mRNA and the protein levels was observed for adenocarcinomas in situ (AISs) and overt carcinomas, closely linked with mucinous differentiation and tumour grades. pS2 scores were inversely related to ERalpha status for all cervical glandular categories, while there was no association with ERbeta and PR values. In squamous lesions, pS2 values did not differ between normal and malignant lesions, in contrast to the significant down-regulation of ERalpha expression with tumour development. Although c-jun expression significantly correlated with ERalpha values for all squamous categories, it did not relate to pS2 status in either C-ACas or ISCCs. These results indicate that alterations in pS2 expression may occur relatively early in the development of cervical glandular, but not squamous lesions, independently of factors known to promote transcription of the pS2 gene.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
cervical adenocarcinoma  IEP 2298570mRNA and protein:increased expression:uterine cervixRGD 
cervical adenocarcinoma  ISOTFF1 (Homo sapiens)2298570; 2298570mRNA and protein:increased expression:uterine cervixRGD 

Objects Annotated

Genes (Rattus norvegicus)
Tff1  (trefoil factor 1)

Genes (Mus musculus)
Tff1  (trefoil factor 1)

Genes (Homo sapiens)
TFF1  (trefoil factor 1)


Additional Information